Navigation Links
Boston Scientific Begins PLATINUM PLUS Trial for PROMUS(R) Element(TM) Stent System
Date:5/25/2010

an," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings, product performance and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statem
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
7. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
8. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2014)... York, NY (PRWEB) November 14, 2014 ... plan, QuickSTAT is making significant investments in its ... world of modern cold chain and the complex ... support QuickSTAT’s ongoing focus on customized logistics and ... and enhancement of existing facilities. There will be ...
(Date:11/15/2014)... The "Operating Room Management Market by Product (Data ... operating room Scheduling), by Component (Software, Services), by ... 2019.” defines and segments the operating room management ... by product, such as data management, anesthesia, surgical ... volumes of operating room management market by applications ...
(Date:11/15/2014)... , November 14, 2014 ... has announced the addition of the  "Protein ... & Services, Application, & by End Users ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The ... valued at $1,569.00 million in 2014, and ...
(Date:11/12/2014)... 2014  ReachBio Research Labs (a registered trade name ... announced today that it has signed an agreement with ... giving Funakoshi non-exclusive distribution rights to ReachBio,s human primary ... within Japan . Under a companion ... services to Japanese drug development companies. Photo ...
Breaking Biology Technology:QuickSTAT Announces Global Expansion Plan to Enhance Its Global Network and Cold Chain Logistics Capabilities for Life Sciences 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4Global Protein Characterization and Identification (Chromatography, Electrophoresis, Mass Spectroscopy) Market - Forecast to 2019 2Global Protein Characterization and Identification (Chromatography, Electrophoresis, Mass Spectroscopy) Market - Forecast to 2019 3Funakoshi to Distribute ReachBio Research Labs Human Primary Cell Products in Japan 2Funakoshi to Distribute ReachBio Research Labs Human Primary Cell Products in Japan 3
... 11, Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA ... ), announced today that,they have entered into a ... Possis Medical in a cash tender offer for ... of approximately US-Dollar 361,million. The offer price represents ...
... a Living ... Cell-Based Therapy, ... to successfully mass-produce living regenerative medicine products,is again breaking new ... living cell-based therapy. As the first,bio-engineered living cell therapy to ...
... Corporation ("AGA"),announced today it received European CE Mark approval ... announced the immediate availability,and launch of the device in ... devices designed to occlude or close a patent ductus ... when a blood vessel,called the ductus arteriosus fails to ...
Cached Biology Technology:Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers 2Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers 3Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers 4AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II 2
(Date:11/4/2014)... only marketing directed at children on the interior ... that the majority of black, middle-income and rural ... , Authored by Arizona State University researcher Punam ... first to examine the use of child-directed marketing ... restaurants and its relationship to demographics. It adds ...
(Date:11/4/2014)... A majority of Madagascar,s 101 species of lemurs are ... for the rainforests they call home. A new study ... can have on rainforest tree populations, which raises concerns ... the region,s rich biodiversity. , A large proportion of ... Lemurs in turn disperse the seeds of their ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and ... "Cell Therapy - Technologies, Markets and Companies" to ... cell therapy technologies and methods, which have already started to ... stem cell transplantation is replacing the old fashioned bone marrow ... Cell therapy is bound to become a part of medical ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... PHILADELPHIA - Mo Salman, professor of animal population health ... 2010 recipient of the Penn Vet World Leadership Award, ... Veterinary Medicine to a veterinarian who has dramatically ... lives of others. The $100,000 in unrestricted funding, ...
... Scientists are reporting the development and successful initial testing of ... designed to be given as nose drops rather than ... brain cancer, they say. The report appears in ACS, ... and colleagues note that brain cancer is difficult to treat, ...
... Imagine devices that capture electricity from the air much ... light a house or recharge an electric car. Imagine using ... before it forms. Strange as it may sound, scientists already ... to a report at the 240th National Meeting of the ...
Cached Biology News:Penn Vet announces $100,000 winners of 2010 World Leadership Award and Student Inspiration Awards 2Penn Vet announces $100,000 winners of 2010 World Leadership Award and Student Inspiration Awards 3Electricity collected from the air could become the newest alternative energy source 2
... Science, which pioneered the blending of thermostable ... and Expand Long Template PCR Systems, now ... the first product of a family ... blend combines Taq DNA Polymerase with a ...
The HEPTEST assays provide a sensitive, simple, rapid, and convenient in vitro quantitation of heparin, low molecular weight heparins, and heparinoids in plasma and whole blood. Sample Type: wh...
...
... Plus DNA Polymerase with a proprietary thermostable ... fidelity than standard Taq DNA polymerase, Double ... Amplifies DNA templates >20kb, Concentration: 5U/ul, Applications: ... cloning and mutagenesis We are part of ...
Biology Products: